Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
OXiGENE Reports Positive Preclinical Ocular Penetration Data with Topical Formulation of ZYBRESTAT(TM) for Ophthalmology Key Feasibility Hurdle Overcome in Topical Ophthalmology Program WALTHAM,...
-
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer Meets Pre-specified Primary Efficacy Endpoint in Stage 1 of Simon Two-Stage Study WALTHAM,...
-
OXiGENE to Report on ZYBRESTAT(TM) Pivotal Trial Progress in Presentation to Investors in Sweden WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 11, 2007--Regulatory News: OXiGENE, Inc. (NASDAQ: OXGN,...
-
OXiGENE's ZYBRESTAT(TM) Reported to Have Anti-Leukemic Effects in Preclinical Studies Published in Blood Results Suggest Broader Clinical Potential for Novel Anti-Cancer Drug Candidate WALTHAM,...
-
OXiGENE To Present at LAZARD Healthcare Conference on November 28 WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 26, 2007--Regulatory News: OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a...
-
OXiGENE REPORTS THIRD QUARTER 2007 RESULTS, CLINICAL AND CORPORATE HIGHLIGHTS WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 1, 2007--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage...
-
OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-Action Data Published in Peer-Review Journal WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 24, 2007--Regulatory News: OXiGENE, Inc....
-
OXiGENE Reports Positive Interim Results from Phase Ib ZYBRESTAT(TM) - Bevacizumab Combination Study in Advanced Solid Tumors Combination Regimen Appears Safe and Well-Tolerated with Early Evidence...
-
OXiGENE To Present at BIO Investor Forum on October 11 WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 4, 2007--Regulatory News: OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a...
-
OXiGENE To Present at UBS Global Life Sciences Conference in NYC September 27 Presentation Available via Webcast WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 19, 2007--Regulatory News: OXiGENE,...